Canada markets close in 6 hours 10 minutes

Therma Bright Inc. (TBRIF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.27110.0000 (0.00%)
As of 02:12PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close0.2711
Open0.2672
BidN/A x N/A
AskN/A x N/A
Day's Range0.2711 - 0.2711
52 Week Range0.1390 - 1.0030
Volume25,088
Avg. Volume25,561
Market Cap62.439M
Beta (5Y Monthly)3.22
PE Ratio (TTM)N/A
EPS (TTM)-0.0300
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Newsfile

    Therma Bright Provides Update on U.S. Clinical Performance Study

    Toronto, Ontario--(Newsfile Corp. - January 20, 2022) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, announced today that its U.S. Clinical Performance Study is still underway. Once the clinical data has been completed and tabulated, the final results will be reported to the marketplace and the U.S. Food & Drug Administration .

  • Newsfile

    Therma Bright AcuVid(TM) COVID-19 Rapid Antigen Saliva Test's Antibodies Successfully Detect the COVID-19 Omicron B.1.1.529 Variant

    Toronto, Ontario--(Newsfile Corp. - December 16, 2021) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to confirm that antibodies incorporated in its AcuVid™ COVID-19 Rapid Antigen Saliva Test have been tested and can successfully detect the new, highly transmissible COVID-19 Omicron B.1.1.529 variant.Ever since the SARS-CoV-2 Novel

  • Newsfile

    Therma Bright Expands Manufacturing Capabilities To Meet New FDA EUA Guidance For AcuVid(TM)

    Agreement with Contract Manufacturer Provides for Production of 500,000 AcuVid(TM) Tests Per Week Toronto, Ontario--(Newsfile Corp. - December 1, 2021) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce it has signed an agreement with a contract manufacturer to produce a weekly minimum of 500,000 AcuVid™ COVID-19 Rapid Anti